Why have this treatment done in China specifically?

China offers the same PD-1/PD-L1 checkpoint inhibitor technology as Keytruda but at approximately one-fifth the cost—around $1,200 per cycle versus $12,000 or more in the U.S. These drugs are NMPA-approved and manufactured in state-of-the-art facilities, with oncologists experienced in high-volume immunotherapy administration. This combination of advanced technology and significant cost savings makes China a compelling destination for this treatment.